# Omega Probability Of Bankruptcy

OMGA | Stock | ## USD 5.13 0.44 7.90% |

Omega |

## Omega Probability Of Bankruptcy Analysis

Omega Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.Probability Of Bankruptcy | = | Normalized | | Z-Score |

## Current Omega Therapeutics Probability Of Bankruptcy | 35% |

Most of Omega Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Omega Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Omega Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Omega Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Omega Therapeutics financial health.

Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Compare to competition |

Based on the latest financial disclosure, Omega Therapeutics has a Probability Of Bankruptcy of 35.0%. This is 19.15% lower than that of the Healthcare sector and 36.18% lower than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 12.13% higher than that of the company.

## Omega Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Omega Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Omega Therapeutics could also be used in its relative valuation, which is a method of valuing Omega Therapeutics by comparing valuation metrics of similar companies.Omega Therapeutics is currently under evaluation in probability of bankruptcy category among related companies.

## Omega Fundamentals

Return On Equity | (49.30) % | |||

Return On Asset | (25.27) % | |||

Current Valuation | 67.41 M | |||

Shares Outstanding | 47.77 M | |||

Shares Owned by Insiders | 3.73 % | |||

Shares Owned by Institutions | 91.20 % | |||

Number of Shares Shorted | 538.79 K | |||

Price to Book | 1.11 X | |||

Price to Sales | 594.87 X | |||

Revenue | 412 K | |||

Gross Profit | (47.72 M) | |||

EBITDA | (71.59 M) | |||

Net Income | (74.96 M) | |||

Cash and Equivalents | 200.8 M | |||

Cash per Share | 4.20 X | |||

Total Debt | 24.18 M | |||

Debt to Equity | 0.13 % | |||

Current Ratio | 15.23 X | |||

Book Value Per Share | 4.61 X | |||

Cash Flow from Operations | (70.41 M) | |||

Short Ratio | 2.07 X | |||

Earnings Per Share | (5.03) X | |||

Number of Employees | 79 | |||

Market Capitalization | 245.09 M | |||

Z Score | 6.0 |

## About Omega Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Omega Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omega Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omega Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Omega Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Omega Therapeutics' short interest history, or implied volatility extrapolated from Omega Therapeutics options trading.

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Omega Therapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please check Omega Therapeutics Piotroski F Score and Omega Therapeutics Altman Z Score analysis. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

## Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.

Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets | Go | |

Stock ScreenerFind equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | Go | |

Piotroski F ScoreGet Piotroski F Score based on binary analysis strategy of nine different fundamentals | Go | |

Competition AnalyzerAnalyze and compare many basic indicators for a group of related or unrelated entities | Go | |

Bond DirectoryFind actively traded corporate debentures issued by US companies | Go | |

Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk | Go | |

Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios. | Go | |

Money ManagersScreen money managers from public funds and ETFs managed around the world | Go | |

Technical AnalysisCheck basic technical indicators and analysis based on most latest market data | Go | |

Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios | Go | |

Fundamental AnalysisView fundamental data based on most recent published financial statements | Go | |

Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | Go | |

ETF DirectoryFind actively traded Exchange Traded Funds (ETF) from around the world | Go |

Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.